Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).

Martin J. van den Bent, Vassilis Golfinopoulos, Marica Eoli et al.|Journal of Clinical Oncology|2018

Cited by 14